Spyre Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Spyre Therapeutics generated cash of -$99,910,000, which is less than the previous year. Cash used in financing activities reached the amount of $361,077,000 last year. Net change in cash is therefore $152,799,000.
Cash Flow
| 2015 | -10.98M | -4.01M | 41.67M |
|---|---|---|---|
| 2017 | -24.61M | -22.52M | 12.21M |
| 2019 | -65.69M | -1.73M | 65.72M |
| 2020 | -75.77M | -7.60M | 154.51M |
| 2021 | -53.71M | -22.61M | 1.39M |
| 2022 | -80.14M | 57.00M | 42.67M |
| 2023 | -99.91M | -108.39M | 361.07M |
SYRE Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 36.41M | 16.98M | 91.93M | 20.75M | 22.46M | 47.74M | 2.61M |
Operating activities | |||||||
Net income | -338.79M | -83.81M | -65.80M | -80.89M | -78.25M | -27.23M | -11.29M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 744K | 1.56M | 1.57M | 996K | 901K | 249K | 89K |
Stock-based compensation expense | 25.67M | 7.11M | 8.03M | 6.25M | 0 | 0 | 767K |
| Deferred income tax benefit | 25.67M | 7.11M | 8.03M | 6.25M | 0 | 0 | 767K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 375K | 440K | 0 | 0 | 0 | -1.86M | -1.69M |
Inventories | 0 | -440K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 218K | -2.64M | 1.06M | -544K | 2.58M | 164K | -169K |
Cash generated by operating activities | -99.91M | -80.14M | -53.71M | -75.77M | -65.69M | -24.61M | -10.98M |
Investing activities | |||||||
Purchases Of Investments | -166.80M | -39.5M | -133.07M | -129M | -91.92M | -64.11M | -3.76M |
Investments In Property Plant And Equipment | 0 | -38K | -573K | -4.28M | -1.49M | -619K | -208K |
Acquisitions Net | 3.03M | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -108.39M | 57.00M | -22.61M | -7.60M | -1.73M | -22.52M | -4.01M |
Financing activities | |||||||
Common Stock Issued | 169.11M | 42.87M | 1.90M | 153.71M | 64.29M | 11.38M | 43.67M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -2.02M |
Repayments of term debt | -16K | -418K | -510K | -20K | -25K | 0 | 0 |
Cash used in financing activities | 361.07M | 42.67M | 1.39M | 154.51M | 65.72M | 12.21M | 41.67M |
Net Change In Cash | 152.79M | 19.43M | -74.95M | 71.18M | -3.20M | -34.93M | 26.67M |
Cash at end of period | 189.21M | 36.41M | 16.98M | 91.93M | 19.25M | 12.81M | 29.29M |
| Data source |